Details for Patent: 7,235,247

Title:	Pharmaceutical composition for application to mucosa
Abstract:	The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high permeability to the blood at the mucosa. The present invention further provides a pharmaceutical composition for application to the mucosa comprising a hemostatic agent and a medicament. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to permeability and retentivity at the mucosa.
Inventor(s):	Nishibe; Yoshihisa (Hino, JP), Kinoshita; Wataru (Hino, JP), Kawabe; Hiroyuki (Tokyo, JP)
Assignee:	Teijin Pharma Limited (Tokyo, JP)
Filing Date:	Jul 24, 2002
Application Number:	10/201,303
Claims:	1. An aqueous pharmaceutical composition for application to the mucosa, comprising one or more water-insoluble and/or low water soluble substance, and one or more medicament, and having an osmotic pressure of 150 mOsm or less. 2. An aqueous pharmaceutical composition for application to the mucosa comprising one or more hemostatic agent, one or more water-insoluble and/or low water soluble substance, and one or more medicament, and having an osmotic pressure of 150 mOsm or less, wherein said hemostatic agent is one or more selected from the group consisting of tranexamic acid, epsilon aminocaproic acid, carbazochrome, carbazochrome sulfonate, carbazochrome sodium sulfonate, phytonadione, etamsylate, monoethanol amine oleate, thrombin, hemocoaglase, and adrenochrome monoaminoguanidine mesilate. 3. The pharmaceutical composition for application to the mucosa according to claim 1 or 2, wherein said osmotic pressure is 90 mOsm or less. 4. The pharmaceutical composition for application to the mucosa according to claim 1, further comprising an osmotic pressure-controlling agent. 5. The pharmaceutical composition for application to the mucosa according to claim 4, wherein said osmotic pressure-controlling agent is a salt. 6. The pharmaceutical composition for application to the mucosa according to claim 4, wherein said osmotic pressure-controlling agent is sodium chloride. 7. The pharmaceutical composition for application to the mucosa according to claim 4, wherein said osmotic pressure-controlling agent is a water-soluble sugar. 8. The pharmaceutical composition for application to the mucosa according to claim 4, wherein said osmotic pressure-controlling agent is glucose. 9. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said water-insoluble and/or low water soluble substance is a cellulose. 10. The pharmaceutical composition for application to the mucosa according to claim 9, wherein said cellulose is crystalline cellulose. 11. The pharmaceutical composition for application to the mucosa according to claim 1 or 2, wherein said one or more water-insoluble and/or low water soluble substance is present as solid particles in an aqueous medium. 12. The pharmaceutical composition for application to the mucosa according to claim 1 or 2 wherein said one or more water-insoluble and/or low water soluble substance is homogeneously dispersed as solid particles in an aqueous medium. 13. The pharmaceutical composition for application to the mucosa according to claim 1 or 2, further comprising a water-soluble polymer substance. 14. The pharmaceutical composition for application to the mucosa according to claim 13, wherein said water-soluble polymer is one or more selected from the group consisting of alginic acid, polyethylene glycol, glycerin, polyoxyethylene polyoxypropylene glycol, propylene glycol, pectin, low methoxyl pectin, guar gum, gum arabic, carrageenan, methyl cellulose, carboxymethyl cellulose sodium, xanthan gum, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose. 15. The pharmaceutical composition for application to the mucosa according to claim 13, wherein said water-soluble polymer is carboxymethyl cellulose sodium. 16. The pharmaceutical composition for application to the mucosa according to claim 13, wherein said water-soluble polymer is xanthan gum. 17. The pharmaceutical composition for application to the mucosa according to claim 13, wherein said water-soluble polymer is hydroxypropyl methyl cellulose. 18. The pharmaceutical composition for application to the mucosa according to claim 13, wherein the combination of said water-insoluble substance and water-soluble polymer is crystalline cellulose carmellose sodium. 19. The pharmaceutical composition for application to the mucosa according to claim 1 or 2, further comprising a surfactant. 20. The pharmaceutical composition for application to the mucosa according to claim 19, wherein said surfactant is polyoxyethylene (20) sorbitan monooleate. 21. The pharmaceutical composition for application to the mucosa according to claim 1 or 2, wherein said medicament is a water-soluble medicament. 22. The pharmaceutical composition for application to the mucosa according to claim 1 or 2, wherein said medicament is a liposoluble medicament. 23. The pharmaceutical composition for application to the mucosa according to claim 1 or 2, wherein said mucosa is nasal mucosa. 24. The pharmaceutical composition for application to the mucosa according to claim 2, wherein the medicament is one or more selected from the group consisting of an antiallergic agent, an antihistamic agent, an anticholinergic agent, a steroid, a vaccine, and a substance for gene therapy, and the mucosa is nasal mucosa. 25. The pharmaceutical composition for application to nasal mucosa according to claim 24, wherein the medicament is a steroid. 26. An aqueous pharmaceutical nasal composition for application to the mucosa, comprising one or more hemostatic agent, one or more water-insoluble and/or low water soluble substance, and one or more medicament, and having an osmotic pressure of 150 mOsm or less. 27. The pharmaceutical composition according to claim 1, wherein the concentration of water-insoluble and/or low water soluble substance is 1% w/w to 10% w/w relative to the total amount of the pharmaceutical composition and the concentration of the medicament is 0.01% w/w to 1% w/w relative to the total amount of the pharmaceutical composition. 28. The composition according to claim 3, wherein the concentration of water-insoluble and/or low water soluble substance is 1% w/w to 10% w/w relative to the total amount of the pharmaceutical composition and the concentration of the medicament is 0.01% w/w to 1% w/w relative to the total amount of the pharmaceutical composition. 29. The pharmaceutical composition according to claim 2, wherein the concentration of water-insoluble and/or low water soluble substance is 1% w/w to 10% w/w relative to the total amount of the pharmaceutical composition and the concentration of the medicament is 0.01% w/w to 1% w/w relative to the total amount of the pharmaceutical composition.